Soligenix, Inc. SNGX
0.34 USD 0.00 (-0.53%)
Nov 10, 2026, 11:13 AM EST
0.3251 Day range 0.3499
0.28 52-week range 1.70
- YTD
- -74.63%
- 1 year
- -75.00%
News
benzinga.com Soligenix Q3 EPS $(0.05) Beats $(0.10) Estimate Soligenix (NASDAQ:SNGX) reported quarterly losses of $(0.05) per share which beat the analyst consensus estimate of $(0.10) by 50 percent. This is a 91.38 percent increase over losses of $(0.58) per…
prnewswire.com Soligenix Announces Recent Updates and Third Quarter 2026 Financial Results PRINCETON, N.J., Nov. 6, 2026 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a biopharmaceutical company focused on developing and commercializing products to treat rare…
benzinga.com Soligenix Q2 EPS $(0.12) Beats $(0.15) Estimate Soligenix (NASDAQ:SNGX) reported quarterly losses of $(0.12) per share which beat the analyst consensus estimate of $(0.15) by 20 percent. This is a 85.37 percent increase over losses of $(0.82) per…
benzinga.com 12 Health Care Stocks Moving In Friday's After-Market Session Gainers China SXT Pharmaceuticals (NASDAQ:SXTC) shares moved upwards by 41.1% to $0.09 during Friday's after-market session. The market value of their outstanding shares is at $12.7 million. iTonic…
benzinga.com Soligenix To Apply For Bundibugyo Ebola Vaccine Development Funding Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet…
benzinga.com U.S. State Dept Announces Nearly $38M In Additional Funding Toward The Department's Ongoing Ebola Response Efforts https://www.state.gov/releases/office-of-the-spokesperson/2026/06/ebola-response-update-june-5-2026/- benzinga.com 12 Health Care Stocks Moving In Wednesday's Intraday Session
benzinga.com 12 Health Care Stocks Moving In Wednesday's Pre-Market Session 
benzinga.com Why Tetra Technologies Shares Are Trading Lower By Over 15%; Here Are 20 Stocks Moving Premarket Tetra Technologies Inc. (NYSE: TTI) shares fell 15.06% in pre-market trading after announcing a $100M stock offering. XOS, Wellchange, and J-Star are top gainers while Jianzhi, NRx, and Volato are…
benzinga.com Crude Oil Falls Over 5%; Dycom Industries Shares Surge Following Q1 Results U.S. stocks traded mixed, Nasdaq down 0.3%. Dow up 0.59%, S&P 500 down 0.09%. Consumer discretionary shares up 1.9%. Dycom Industries reports strong earnings.- benzinga.com 12 Health Care Stocks Moving In Wednesday's Intraday Session
benzinga.com Dow Jumps Over 300 Points; Dick's Sporting Shares Fall After Q1 Results US stocks mixed, Dow up 300 pts. Dow up 0.64%, NASDAQ down 0.34%. Consumer discretionary up 1.7%, energy down 1.9%. DKS stock falls 5% on mixed results.
benzinga.com Why Semtech Shares Are Trading Higher By 7%; Here Are 20 Stocks Moving Premarket Semtech Corp (SMTC) reported strong Q1 financial results, beating analysts' estimates. Shares rose 7% in pre-market trading as Q2 guidance exceeded expectations.
benzinga.com Soligenix (SNGX) Stock Soars 72% On ThermoVax Platform Promise Amid Ebola Outbreak Caused By Bundibugyo Virus Soligenix shares surged 72.32% in after-hours trading following rapid Bundibugyo virus vaccine development announcement.- benzinga.com 12 Health Care Stocks Moving In Tuesday's After-Market Session
benzinga.com U.S. CDC Says Will Enhance Screening And Monitoring Of Travelers Arriving From Areas Affected By Ebola Outbreaks; Will Coordinate With Airlines, Others To Manage Travelers Who May Have Already Been Exposed To Ebola; Will Enhance Contract Tracing, Hospital Readiness Nationwide https://www.cdc.gov/ebola/situation-summary/index.html- benzinga.com Soligenix Q1 EPS $(0.28), Inline Soligenix (NASDAQ:SNGX) reported quarterly losses of $(0.28) per share which met the analyst consensus estimate. This is a 73.58 percent increase over losses of $(1.06) per share from the same period…
- benzinga.com 12 Health Care Stocks Moving In Wednesday's Intraday Session
- benzinga.com 12 Health Care Stocks Moving In Tuesday's Intraday Session
benzinga.com Crude Oil Gains Over 3%; General Motors Earnings Top Views US stocks down, NASDAQ falls over 1% on Tuesday. Dow up 0.20%, NASDAQ down 1.24%, S&P 500 down 0.65%. GM reports better-than-expected Q1 results.
benzinga.com Why Is Soligenix Stock Sinking Tuesday? Soligenix ends Phase 3 FLASH2 study for HyBryte. CEO cites unanticipated results. See how this impacts SNGX and next steps.
benzinga.com Dow Gains 150 Points; Coca-Cola Posts Upbeat Earnings US stocks mixed with Dow up 150 pts. Dow up 0.27%, NASDAQ down 1.06%, S&P 500 down 0.52%. Energy shares up 1.7%. Coca-Cola beats earnings & raises guidance. Baiya Int'l up 126%, Nexera up 63%,…- benzinga.com 12 Health Care Stocks Moving In Tuesday's Pre-Market Session
- benzinga.com The Data Monitoring Committee Recommends Soligenix To Halt Phase 3 FLASH2 Trial Of HyBryte (Synthetic Hypericin) For Cutaneous T-cell lymphoma For Futility Soligenix, Inc. (NASDAQ:SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet…
benzinga.com Soligenix Announces Publication Of Comparability Study Results Evaluating HyBryte Versus Valchlor For Treatment Of Cutaneous T-Cell Lymphoma In Oncology And Therapy HyBryte™ demonstrates more rapid and robust treatment response compared toValchlor® during 12-week treatment coursePRINCETON, N.J., April 2, 2026 /PRNewswire/ -- Soligenix, Inc. (NASDAQ:SNGX)…
benzinga.com Soligenix Q4 EPS $(0.29) Beats $(0.56) Estimate Soligenix (NASDAQ:SNGX) reported quarterly losses of $(0.29) per share which beat the analyst consensus estimate of $(0.56) by 48.75 percent. This is a 74.82 percent increase over losses of $(1.14)…- benzinga.com Soligenix Secures EU Orphan Drug Status For Rare Disease Treatment, Designation Provides 10-Year Market Exclusivity And Development Support Soligenix, Inc. (NASDAQ:SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet…
- benzinga.com Soligenix Says Summary Of All Clinical Trials Completed To Date Of Hybryte (Synthetic Hypericin) For Cutaneous T-Cell Lymphoma Has Been Published In The Peer-reviewed Medical Journal Expert Opinion On Investigational Drugs Expert Opinion on Investigational Drugs is an international monthly peer-reviewed journal, evaluating drugs in preclinical and clinical development. Authors are encouraged to express their Expert…
- benzinga.com Watching Soligenix; Zacks Small-Cap Research Gives Stock $25.00 Price Valuation https://s27.q4cdn.com/906368049/files/News/2026/Zacks_SCR_Research_03122026_SNGX_Bautz.pdf
- benzinga.com Soligenix's SGX945 (Dusquetide) Receives Promising Innovative Medicine Designation In U.K. For Behçet's Disease Soligenix, Inc. (NASDAQ:SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet…
benzinga.com 12 Health Care Stocks Moving In Monday's Pre-Market Session - benzinga.com Soligenix Enters $3.45M At-The-Market Equity Sales Agreement With Rodman & Renshaw Item 8.01.Other Events. On January 23, 2026, Soligenix, Inc. (the "Company") and Rodman & Renshaw, LLC ("Rodman") entered into an At Market Issuance Sales Agreement (as amended, the "Sales…
- benzinga.com Soligenix Announces Results From Phase 2a Proof Of Concept Study Evaluating SGX945 In Treatment Of Behçet's Disease Published In Rheumatology (Oxford) Study results support advancing SGX945 in this difficult-to-treat orphan diseaseResults suggest potential durability of response for maintenance therapyPRINCETON, N.J., Dec. 18, 2025 /PRNewswire/ --…
benzinga.com Soligenix Psoriasis Trial Extension Shows Better Outcomes With New Gel Soligenix reports positive Phase 2a extension results for SGX302 gel in psoriasis, showing improved skin scores and strong tolerability.- benzinga.com Soligenix Announced Extended Results Of Its Ongoing Phase 2a Trial Of SGX302 (Synthetic Hypericin) For Mild-to-moderate Psoriasis The Cohort 3 patients were treated for the same 18-week period as Cohorts 1 and 2, but utilized an optimized gel formulation of synthetic hypericin. The gel formulation was specifically designed to…
- benzinga.com Soligenix Completes Planned Enrollment Of 50 Patients Necessary For Interim Analysis In 80 Patient Confirmatory Phase 3 Double-Blind, Placebo-Controlled Study Evaluating HyBryte In CTCL Treatment 50 of 80 patients enrolled in FLASH2 study Blinded Response Rate to Date Exceeds Trial EstimatePRINCETON, N.J., Nov. 19, 2025 /PRNewswire/ -- Soligenix, Inc. (NASDAQ:SNGX) (Soligenix or the Company),…
- benzinga.com Soligenix Q3 EPS $(0.58) Misses $(0.56) Estimate Soligenix (NASDAQ:SNGX) reported quarterly losses of $(0.58) per share which missed the analyst consensus estimate of $(0.56) by 4.5 percent. This is a 25.64 percent increase over losses of $(0.78)…
- benzinga.com Soligenix Updates U.S. Medical Advisory Board To Guide Phase 3 HyBryte Development For CTCL Providing Strategic Medical Guidance in Advancing HyBryte™ Clinical DevelopmentPRINCETON, N.J., Oct. 14, 2025 /PRNewswire/ -- Soligenix, Inc. (NASDAQ:SNGX) (Soligenix or the Company), a late-stage
- benzinga.com Soligenix Reports No Safety Concerns In First DMC Review Of Phase 3 HyBryte Trial For CTCL FLASH2 Study Interim Efficacy Analysis Targeted for 1H2026Enrollment Update Remains on Track for 4Q2025PRINCETON, N.J., Oct. 7, 2025 /PRNewswire/ -- Soligenix, Inc. (NASDAQ:SNGX) (Soligenix or the…
- benzinga.com Soligenix Expands European MAB To Provide Addl Medical/Clinical Strategic Guidance As It Advances Confirmatory Phase 3 Placebo-Controlled Study Evaluating Safety And Efficacy Of HyBryte In CTCL Treatment In preparation for health authority interactions in pursuit of marketing approvals in Europe PRINCETON, N.J., Sept. 30, 2025 /PRNewswire/ -- Soligenix, Inc. (NASDAQ:SNGX) (Soligenix or the Company), a
benzinga.com 12 Health Care Stocks Moving In Friday's Intraday Session Gainers Indaptus Therapeutics (NASDAQ: INDP) stock moved upwards by 108.1% to $6.83 during Friday's regular session. The market value of their outstanding shares is at $3.6 million.- benzinga.com 12 Health Care Stocks Moving In Friday's Pre-Market Session Gainers bioAffinity Technologies (NASDAQ: BIAF) stock increased by 71.8% to $5.86 during Friday's pre-market session. The company's market cap stands at $4.5 million.
- benzinga.com 12 Health Care Stocks Moving In Tuesday's After-Market Session
- benzinga.com 12 Health Care Stocks Moving In Tuesday's Intraday Session
benzinga.com 5 Healthcare Stocks On Fire This Week Healthcare stocks SNOA, EVOK, KALA, DNA, & SNGX soar with massive momentum gains, signaling breakout potential in biotech & pharma.
benzinga.com Why Rocket Pharmaceuticals Shares Are Trading Higher By Over 15%; Here Are 20 Stocks Moving Premarket - benzinga.com 12 Health Care Stocks Moving In Tuesday's Intraday Session
benzinga.com US Stocks Mixed; Home Depot Shares Gain After Q2 Results - benzinga.com 12 Health Care Stocks Moving In Tuesday's Pre-Market Session
benzinga.com Why Palo Alto Shares Are Trading Higher By Around 7%; Here Are 20 Stocks Moving Premarket